Neurodegenerative Disorders A Clinical Guide
Neurodegenerative Disorders provides an accessible guide to the commonest neurodegenerative diseases, outlining the main clinical features, treatment options and outcomes of the conditions most frequently encountered in clinical practice. Beginning with a
- PDF / 7,719,400 Bytes
- 308 Pages / 439.37 x 666.142 pts Page_size
- 103 Downloads / 214 Views
Orla Hardiman • Colin P. Doherty (Editors)
Neurodegenerative Disorders A Clinical Guide
Editors Orla Hardiman, BSc, MB, BCh, BAO, MD FRCPI, FAAN HRB Clinician Scientist Consultant Neurologist and Clinical Professor, Department of Neurology Beaumont Hospital and Trinity College Dublin Ireland
Colin P. Doherty, MB, BCh, BAO MD, FRCPI Consultant Neurologist and Honorary Senior Lecturer, Departments of Neurology and Clinical Neurological Sciences St. James’s Hospital and the Royal College of Surgeons in Dublin, Dublin Ireland
ISBN 978-1-84996-010-6 e-ISBN 978-1-84996-011-3 DOI 10.1007/978-1-84996-011-3 Springer London Dordrecht Heidelberg New York British Library Cataloguing in Publication Data A catalogue record for this book is available from the British Library Library of Congress Control Number: 2011930952 © Springer-Verlag London Limited 2011 Whilst we have made considerable efforts to contact all holders of copyright material contained in this book, we may have failed to locate some of them. Should holders wish to contact the Publisher, we will be happy to come to some arrangement with them. Apart from any fair dealing for the purposes of research or private study, or criticism or review, as permitted under the Copyright, Designs and Patents Act 1988, this publication may only be reproduced, stored or transmitted, in any form or by any means, with the prior permission in writing of the publishers, or in the case of reprographic reproduction in accordance with the terms of licences issued by the Copyright Licensing Agency. Enquiries concerning reproduction outside those terms should be sent to the publishers. The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore free for general use. Product liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature. Cover design: eStudioCalamar, Figueres/Berlin Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com)
Foreword
Neurodegeneration has never been a very attractive way to describe a group of diseases. It says nothing about causes and lumps together a vast array of very different conditions. It also arises from an era which was completely devoid of any notion of cause or any hope of treatment. I remember being told by one of my most distinguished mentors in neurology that there had not been a single good idea about ALS since it was clearly described by Charcot in the nineteenth century. As recently as the latter quarter of the twentieth century, people who decided to work on one of these so-called degenerative conditions were felt to have descended into a hopeless morass, out of which there was no academic escape. The first crack in the icicle came with the discovery of l-dopa to tr
Data Loading...
